Olson Karin B, Hellie C Michael, Pienta Kenneth J
Michigan Urology Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
Urology. 2005 Sep;66(3):658. doi: 10.1016/j.urology.2005.03.028.
Intravenous bisphosphonates are widely used in the management of metastatic bone disease, as well as osteoporosis. Recent published reports have documented a possible link between treatment with intravenous bisphosphonates and osteonecrosis of the jaw. We report a case of osteonecrosis of the jaw in 1 patient with prostate cancer receiving both chemotherapy and intravenous zoledronic acid (Zometa). Bisphosphonates have been demonstrated to alter the normal bone microenvironment and appear to have direct effects on tumors as well. These changes may contribute to the development of osteonecrosis of the jaw, particularly after tooth extractions or other invasive dental procedures.
静脉注射双膦酸盐广泛应用于转移性骨病以及骨质疏松症的治疗。最近发表的报告记录了静脉注射双膦酸盐治疗与颌骨坏死之间可能存在的联系。我们报告了1例接受化疗和静脉注射唑来膦酸（择泰）的前列腺癌患者发生颌骨坏死的病例。双膦酸盐已被证明会改变正常的骨微环境，并且似乎对肿瘤也有直接影响。这些变化可能促使颌骨坏死的发生，尤其是在拔牙或其他侵入性牙科手术后。
